- Home
- VIVS vs ADIL Comparison
VIVS vs ADIL Comparison
Compare VIVS & ADIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VIVS
- ADIL
- Stock Information
- Founded
- VIVS 2007
- ADIL 2010
- Country
- VIVS United States
- ADIL United States
- Employees
- VIVS N/A
- ADIL N/A
- Industry
- VIVS Biotechnology: Biological Products (No Diagnostic Substances)
- ADIL Biotechnology: Pharmaceutical Preparations
- Sector
- VIVS Health Care
- ADIL Health Care
- Exchange
- VIVS Nasdaq
- ADIL Nasdaq
- Market Cap
- VIVS 8.1M
- ADIL 7.7M
- IPO Year
- VIVS N/A
- ADIL 2018
- Fundamental
- Price
- VIVS $2.28
- ADIL $0.38
- Analyst Decision
- VIVS
- ADIL Strong Buy
- Analyst Count
- VIVS 0
- ADIL 2
- Target Price
- VIVS N/A
- ADIL $4.75
- AVG Volume (30 Days)
- VIVS 104.1K
- ADIL 733.6K
- Earning Date
- VIVS 11-12-2025
- ADIL 11-12-2025
- Dividend Yield
- VIVS N/A
- ADIL N/A
- EPS Growth
- VIVS N/A
- ADIL N/A
- EPS
- VIVS N/A
- ADIL N/A
- Revenue
- VIVS $142,000.00
- ADIL N/A
- Revenue This Year
- VIVS $42.38
- ADIL N/A
- Revenue Next Year
- VIVS $15.42
- ADIL N/A
- P/E Ratio
- VIVS N/A
- ADIL N/A
- Revenue Growth
- VIVS 94.52
- ADIL N/A
- 52 Week Low
- VIVS $1.41
- ADIL $0.22
- 52 Week High
- VIVS $21.96
- ADIL $1.30
- Technical
- Relative Strength Index (RSI)
- VIVS 38.84
- ADIL 53.47
- Support Level
- VIVS $2.14
- ADIL $0.35
- Resistance Level
- VIVS $2.44
- ADIL $0.39
- Average True Range (ATR)
- VIVS 0.27
- ADIL 0.03
- MACD
- VIVS -0.09
- ADIL -0.00
- Stochastic Oscillator
- VIVS 10.00
- ADIL 41.56
About VIVS VivoSim Labs Inc. Common Stock
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.
About ADIL Adial Pharmaceuticals Inc
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder. The active ingredient in AD04 is ondansetron, a serotonin-3 antagonist.